In Segment C, participants will receive ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Contributors will obtain treatment till ailment progression or perhaps the individuals are not able to tolerate the study drugs. Ubiquitin-associated proteins that control The soundness of essential super enhancer-mediated proteins have https://abbv-744-preclinical-stud35680.blogunteer.com/31214737/the-fact-about-new-advancements-in-brd4-inhibition-therapy-abbv-744-that-no-one-is-suggesting